Clinical Trial: A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07667868) titled 'A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma' on June 19.

Brief Summary: The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.

Study Start Date: Oct. 01, 2026

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Multiple Myeloma (RRMM)

Intervention: BIOLOGICAL: BP2202

Intravenous infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: BrightPath Biotherapeutics Co., Ltd.

Disclaimer: Curated by HT Syndication....